AXSOME THERAPEUT. DL-0001 WKN: A2AA7B ISIN: US05464T1043 Kürzel: AXSM Forum: Aktien Thema: Hauptdiskussion

https://uk.finance.yahoo.com/news/axsome-therapeutics-initiates-focus-2-110000176.html

https://goldesel.de/aktien/news/axsome-therapeutics-lost-sunosi-patentrechtsstreit-vergleich-senkt-ungewissheit-generika-erst-ab-2040

https://goldesel.de/aktien/news/axsome-erhalt-fda-zulassung-fur-auvelity-bei-alzheimer-agitation-aktie-profitiert-nach-pdufa

Heute PDUFA-Termin für AXS-05 (Alzheimer Agitation). Sollte also heute/morgen Bewegung reinkommen

Eine der besten Bio buden

Die Aktie macht doch einfach nur Spaß. Bestes Pferd im Stall!

https://finance.yahoo.com/sectors/healthcare/articles/axsome-therapeutics-acquires-selective-pde10a-110000091.html

Still geworden hier

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-forward-phase-3-trial-axs-14

😁

meinen Glückwunsch an alle investiert. 🥂😉👍🏻

https://stocktwits.com/news-articles/equity/markets/axsome-advances-toward-fda-filing-for-drug-to-treat-narcolepsy/cL7B4KPREzL

👀

Axsome Therapeutics (NASDAQ: AXSM) received formal FDA pre-NDA meeting minutes supporting an NDA submission for AXS-12 (reboxetine) to treat cataplexy in narcolepsy. The FDA agreed the company’s regulatory data package would be sufficient for an NDA filing. Axsome anticipates completing the NDA submission in January 2026, with acceptance subject to the FDA’s review of the complete filing. AXS-12 clinical work includes three controlled efficacy trials and a completed long-term safety trial. AXS-12 holds Orphan Drug Designation, which may provide seven years of U.S. market exclusivity and potential user-fee waiver if approved.